WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (34)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, M. A.
Right arrow Articles by Pasternak, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, M. A.
Right arrow Articles by Pasternak, G. W.

 Previous Article  |  Next Article 

The Journal of Neuroscience, October 1, 2001, 21(19):7788-7792

Potentiation of Opioid Analgesia in Dopamine2 Receptor Knock-Out Mice: Evidence for a Tonically Active Anti-Opioid System

Michael A. King1, Sheri Bradshaw2, Albert H. Chang1, John E. Pintar2, and Gavril W. Pasternak1

1 Laboratory of Molecular Neuropharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and 2 Department of Neuroscience and Cell Biology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Dopamine systems are intimately involved with opioid actions. Pharmacological studies suggest an important modulatory effect of dopamine and its receptors on opioid analgesia. We have now examined these interactions in a knock-out model in which the dopamine2 (D2) receptor has been disrupted. Loss of D2 receptors enhances, in a dose-dependent manner, the analgesic actions of the µ analgesic morphine, the kappa 1 agonist U50,488H and the kappa 3 analgesic naloxone benzoylhydrazone. The responses to the delta  opioid analgesic [D-Pen2,D-Pen5]enkephalin were unaffected in the knock-out animals. Loss of D2 receptors also potentiated spinal orphanin FQ/nociceptin analgesia. Antisense studies using a probe targeting the D2 receptor revealed results similar to those observed in the knock-out model. The modulatory actions of D2 receptors were independent of sigma  receptor systems because the sigma  agonist (+)-pentazocine lowered opioid analgesia in all mice, including the D2 knock-out group. Thus, dopamine D2 receptors represent an additional, significant modulatory system that inhibits analgesic responses to µ and kappa  opioids.

Key words: analgesia; dopamine; dopamine receptor; D2 receptor; knock-out; antisense; anti-opioid; nociception; analgesic


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Dopamine-opioid interactions have been widely studied. Anatomically, opioid and dopamine systems are closely related (Khachaturian and Watson, 1982) and their interactions are functionally significant. Neurochemically, opioids influence dopamine release (Wood et al., 1980; Wood, 1983; Wood and Pasternak, 1983) and therefore prolactin release (Wood et al., 1980; Spiegel et al., 1982; Wood and Pasternak, 1983; Brent and Bunn, 1994). Chronic haloperidol upregulates enkephalin levels (Hong et al., 1978) and dopamine agonists upregulate the expression of µ opioid receptor mRNA (Azaryan et al., 1996), whereas opioid treatment downregulates [3H]spiperone binding (Brent and Bunn, 1994).

The dopamine system also influences opioid behaviors. The study of dopamine systems in opioid anti-nociception goes back 30 years (Calcutt et al., 1971; Tulunay et al., 1975; Rodgers, 1977; McGilliard and Takemori, 1979). These early studies reported lowered opioid analgesia after activation of dopamine systems and enhanced analgesia with dopamine receptor antagonists. More recent studies support these initial observations, including some looking at specific dopamine2 (D2) receptor drugs. The dopamine D2 receptor agonist quinpirole (Kamei and Saitoh, 1996) and the dopamine precursor L-3,4-dihydroxyphenylalanine (Kunihara et al., 1993) both lower the analgesic activity of morphine. The D2 antagonist (-)-sulpiride potentiates the analgesic actions of the µ-selective opioid sulfentanil, whereas the D1 receptor antagonist SCH23390 was without effect (Rooney and Sewell, 1989), implying that a tonically active D2 receptor system downregulates opioid analgesia.

However, others report that activation of dopamine systems can facilitate analgesic systems (Bodnar and Nicotera, 1982). The D2 receptor agonist RU24926 is analgesic in mice and the response is blocked by both D2 receptor antagonists and the opioid antagonist naloxone (Michael-Titus et al., 1990; Suaudeau and Costentin, 1995). In the formalin test, a D2 antagonist diminished morphine analgesia, whereas the D2 agonist quinpirole elicited analgesia (Morgan and Franklin, 1991), an action quite different from that seen by others using a thermal paradigm (Kamei and Saitoh, 1996). Thus, dopamine has complex effects on opioid systems and is able to facilitate and/or inhibit opioid analgesia.

Opioid analgesia also is modulated by a tonically active anti-opioid sigma 1 receptor system that can be activated by the sigma 1 agonist (+)-pentazocine and blocked by haloperidol (Chien and Pasternak, 1993, 1994, 1995a,b). The existence of this system has been confirmed using antisense approaches against the cloned sigma  receptor in both mice and rats (Pan et al., 1998; Mei and Pasternak, 2001). Although the actions of haloperidol on opioid analgesia clearly involve sigma  receptors, the possibility of an additional role for dopamine D2 receptors remains based on the high affinity of haloperidol for both sigma 1 and D2 receptors. Knock-out strategies offer a unique approach toward defining the roles of specific proteins in behavior. For example, a D2 knock-out mouse demonstrated the importance of D2 dopamine receptors in the rewarding behavior of morphine (Maldonado et al., 1997). To explore the relationship of dopamine D2 receptors to sigma 1 receptors and their modulation of opioid analgesia we have examined the effects of disruption of D2 receptors on opioid analgesia.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Morphine sulfate, morphine-6beta -glucuronide (M6G), [D-Pen2,D-Pen5]enkephalin (DPDPE), and U50,488H were gifts from the Research Technology Branch of the National Institute on Drug Abuse (Bethesda, MD). (+)-Pentazocine was a gift from Sanofi-Winthrop (New York, NY). (-)-Sulpiride was purchased from Sigma (St. Louis, MO). Naloxone benzoylhydrazone (NalBzoH) was synthesized as described previously (Luke et al., 1988). Clonidine was purchased from Research Biochemicals International (Natick, MA). Halothane was purchased from Halocarbon Laboratory (Hackensack, NJ). Orphanin FQ/nociceptin (OFQ/N) was synthesized by the Core Facility at Memorial Sloan-Kettering Cancer Center and purified by HPLC; its structure was verified by mass spectroscopy.

Male Crl:CD-1(ICR)BR mice (24-32 gm) were purchased from Charles River Laboratories (Raleigh, VA). The mutated mice were generated as described previously (Jung et al., 1999). Mice were generated from heterozygous matings of mice derived from a cross of C57BL6/J × 129/SwEv and were maintained on a 12 hr light/dark cycle with food and water available ad libitum. The drugs were administered subcutaneously, intracerebroventricularly (Haley and McCormick, 1957), or intrathecally (Hylden and Wilcox, 1980). Analgesia was assessed quantally using the radiant heat tailflick assay with baseline latencies ranging from 2 to 3 sec, as described previously (King et al., 1997a). A 10 sec cutoff was imposed to minimize tissue damage. Analgesia was defined quantally as a doubling or greater of the baseline latency for the individual mouse. Group comparisons were performed using Fisher's exact test. A modification of the Litchfield and Wilcoxon method was used to determine ED50 values and 95% confidence limits (Tallarida and Murray, 1987).

The dopamine D2 receptor antisense oligodeoxynucleotide sequence was based on the mouse D2 receptor sequence (Montmayeur et al., 1991; Guiramand et al., 1995). The oligodeoxynucleotide was synthesized by Midland Certified Reagent Co. (Midland, TX), purified in our laboratory, and dissolved in 0.9% saline. Antisense A (GGT TGG CTC TGA AAG CTC GGC) corresponds to nucleotides 755-775. The mismatch oligodeoxynucleotide (GGT GTG CTC TAG AAG TCC GGC) is based on antisense A and differs only in the sequence of six bases (underlined). Male Crl:CD-1(ICR)BR mice received antisense A (5.0 µg/2.0 µl, i.c.v.) on days 1, 3, and 5 and were tested for analgesia on day 6, as described previously (Standifer et al., 1994; King et al., 1997a).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

First, we explored the role of D2 dopamine receptors in modulating opioid analgesia by examining the effects of the dopamine D2 antagonist sulpiride on morphine analgesia. A low dose of morphine was used to facilitate our ability to detect an increased analgesic response. Sulpiride enhanced morphine analgesia in wild-type mice, increasing the response from only 10% to 60% (Fig. 1). In contrast, sulpiride had no effect on morphine analgesia in the knock-out mice, suggesting that its potentiation of analgesia in the wild-type mice reflected dopamine D2 receptor blockade.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1.   Sulpiride effect on morphine analgesia. Dopamine2 receptor knock-out mice (n >=  10) received morphine (2 mg/kg, s.c.) and (-)-sulpiride (10 mg/kg, s.c.). Analgesia was assessed 30 min later. (-)-Sulpiride significantly potentiated morphine analgesia in the wild-type animals (*p < 0.03) but not in the homozygous animals.

These initial experiments showed that morphine alone was more potent in the knock-out mice than in the wild-type group (Fig. 1). To explore this observation further, we examined the analgesic actions of various opioids in wild-type, heterozygous, and knock-out mice in which the D2 receptor had been disrupted. Supraspinally, the D2 receptor knock-out mice were significantly more sensitive to the µ drugs morphine and M6G, the kappa 1 analgesic U50,488H, and the kappa 3 drug NalBzoH (Fig. 2A). The heterozygotes gave intermediate responses. In contrast, the delta  drug DPDPE given supraspinally had similar activities in the wild-type and knock-out groups. Supraspinal OFQ/N had little effect in any of the groups. Spinally, we observed a slightly different pattern (Fig. 2B). Morphine, M6G, and U50,488H still produced far greater responses in the knock-out mice, whereas DPDPE analgesia was unaffected. However, OFQ/N analgesia at the spinal level was significantly enhanced in the knock-out mice.



View larger version (40K):
[in this window]
[in a new window]
  		Figure 2.   Effects of centrally administered opioid analgesics in D2 knock-out mice. A, Groups of mice (n >=  10) received the indicated drugs [morphine (233 ng, i.c.v.), M6G (4 ng, i.c.v.), DPDPE (4 µg, i.c.v.), U50,488H (25 µg, i.c.v.), or NalBzoH (15 µg, i.c.v.)] supraspinally, and analgesia was assessed by tailflick assay. Results are the percentage of mice that were analgesic, defined quantally as a doubling or greater of their baseline values; *p < 0.01. B, Groups of mice (n >=  10) received morphine (233 ng, i.t.), M6G (4 ng, i.t.), DPDPE (0.3 µg, i.t.), U50,488H (25 µg, i.t.), NalBzoH (15 µg, i.t.), or OFQ (5 µg, i.t.) spinally, and analgesia was assessed by tailflick assay. Results are the percentage of mice that were analgesic, defined quantally as a doubling or greater of their baseline values; *p < 0.01.

Systemic administration gave results that were similar to those seen with central injections (Fig. 3). Dose-response curves with morphine, M6G, U50,488H, and NalBzoH all revealed significant shifts to the left in the knock-out groups. The sensitivity of the knock-out mice to morphine and M6G analgesia was enhanced more than twofold, but even greater effects were observed with the kappa  drugs. The response curve for the kappa 1 analgesic U50,488H was shifted 12-fold to the left and the curve for the kappa 3 agent NalBzoH was shifted fivefold (Table 1).



View larger version (27K):
[in this window]
[in a new window]
  		Figure 3.   Effects of systemic opioid analgesics in D2 knock-out mice. Cumulative dose-response curves were generated in groups of mice (n >=  10) for morphine, M6G, U50,488H, or NalBzoH. All mice in the group received the lowest drug dose, and analgesia was assessed 30 min later. Animals that were not analgesic at the first dose then received a second dose and were tested 30 min afterward. This same procedure was then repeated until all mice were analgesic. The ED50 values (95% confidence limits) are presented in Table 1.


                              
View this table:
[in this window]
[in a new window]
  		Table 1.   ED50 values for opioids in D2 knock-out mice

To ensure that the effects seen in the knock-out mice were attributable to the loss of the targeted protein and not to more generalized developmental changes secondary to the loss of the D2 receptor, we also used an antisense approach in adult mice. D2 antisense approaches have been widely reported in the literature (Weiss et al., 1993, 1997; Zhang and Creese, 1993; Creese and Tepper, 1998). An antisense oligodeoxynucleotide given supraspinally and targeting the D2 receptor enhanced the analgesic actions of morphine, M6G, U50,488H, and NalBzoH (Fig. 4). As in the knock-out mice, DPDPE analgesia was unchanged. The effect was specific because a mismatch probe with minor sequence changes was inactive.



View larger version (40K):
[in this window]
[in a new window]
  		Figure 4.   Effect of dopamine D2 receptor antisense on opioid analgesia. Groups of CD-1 mice (n >=  20) received saline or the indicated oligodeoxynucleotide (5 µg, i.c.v.) on days 1, 3, and 5. On day 6 all mice were tested with morphine (3 mg/kg, s.c.), M6G (2.5 mg/kg, s.c.), DPDPE (4 µg, i.c.v.), U50,488H (2 mg/kg, s.c.), or NalBzoH (30 mg/kg, s.c.), and analgesia was assessed quantally. Antisense A significantly potentiated morphine, M6G, U50,488H, and NalBzoH analgesia; *p < 0.01; **p < 0.001.

(+)-Pentazocine reverses opioid analgesia despite its inability to bind to opioid receptors, an action that has been attributed to activation of sigma 1 receptors (Chien and Pasternak, 1993, 1994). To explore the relationship between the sigma  and D2 systems, we subsequently examined the effects of the sigma  ligand (+)-pentazocine in the D2 knock-out animals. (+)-Pentazocine (5 mg/kg, s.c.) lowered morphine analgesia in all three groups of mice (Fig. 5A). In all cases, the actions of (+)-pentazocine were blocked by the concurrent administration of haloperidol. Although haloperidol binds to both sigma  and dopamine D2 receptors with similar high affinities, its continued activity in the knock-out group lacking dopamine D2 receptors confirms a sigma  receptor mechanism of action in this model.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 5.   (+)-Pentazocine and haloperidol modulation of morphine analgesia. A, Groups of mice (n >=  10) received morphine (5 mg/kg, s.c.) and (+)-pentazocine (3 mg/kg, s.c.) alone, (+)-pentazocine (3 mg/kg, s.c.) with haloperidol (0.1 mg/kg, s.c.), or nothing. Analgesia was assessed 30 min later. (+)-Pentazocine significantly lowered the analgesic response in all three groups (*p < 0.01). B, Groups of mice (n >=  14) received morphine (2 mg/kg, s.c.) alone or with haloperidol (0.1 mg/kg, s.c.). Haloperidol significantly increased the analgesic responses in the heterozygotes (p < 0.003) and in the knock-out mice (*p < 0.003; **p < 0.02).

Finally, we examined the effects of haloperidol directly on morphine analgesia using a low dose of the opioid (Fig. 5B). Haloperidol enhanced the morphine response in all three groups, with the most significant effects observed in the heterozygotes and the knock-out mice. This observation demonstrated that the D2 receptor knock-out mice retained a tonically active anti-opioid sigma  system and showed conclusively that the anti-opioid D2 and sigma  systems are distinct.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The modulation of the opioid analgesia by other transmitters is quite complex. A number of transmitters decrease the sensitivity of animals to opioid analgesics, including sigma  receptor agonists (Chien and Pasternak, 1993, 1994, 1995a,b), orphanin FQ/nociceptin (Grisel et al., 1996; Mogil et al., 1996; Tian et al., 1997; King et al., 1998), cholecystokinin (Faris et al., 1983; Cesselin, 1995; Nichols et al., 1995; Xu et al., 1996b), and neuropeptide FF (Cesselin, 1995; Roumy and Zajac, 1998). Traditional pharmacological studies suggested a similar anti-opioid activity of dopamine D2 receptors (Rooney and Sewell, 1989; Kunihara et al., 1993; Kamei and Saitoh, 1996), a concept which is supported by the current study.

Disruption of D2 receptors potentiated opioid analgesia, but not all opioid systems were affected similarly. µ Analgesia was enhanced both spinally and supraspinally, but the greatest effects were seen with the kappa  drugs. kappa  Analgesia is often not as easily demonstrated as µ analgesia, perhaps because of activity of anti-opioid systems. This was clearly shown in studies looking at the effects of sigma  receptors for which antagonism of sigma  sites enhanced kappa  analgesics more prominently than µ drugs and even accounted for some of the differences in sensitivity of mouse strains to these drugs (Chien and Pasternak, 1993, 1994, 1995b; King et al., 1997a; Pan et al., 1998). Because many clinical analgesics have kappa  activity, these findings raise the possibility that concurrent use of D2 antagonists with these drugs might increase their utility in pain management.

Disrupting the D2 receptor had little effect on delta  analgesia, emphasizing the differences among the opioid analgesic systems. The pharmacology of OFQ/N supraspinally is quite complex, with hyperalgesic (Meunier et al., 1995; Reinscheid et al., 1995), anti-opioid (Grisel et al., 1996; Mogil et al., 1996; King et al., 1998), and analgesic activities (Rossi et al., 1996, 1997) depending on the paradigm, dose, time course, and even strain of mouse. Supraspinal OFQ/N analgesia was not seen in these studies. Previously, we were able to detect significant supraspinal OFQ/N analgesia only in conjunction with haloperidol (Rossi et al., 1996). The inability to detect appreciable OFQ/N analgesia in the D2 knock-out mice would suggest that the actions of haloperidol in these previous studies were attributable to the blockade of sigma 1 and not D2 receptors. Several studies have documented a more robust analgesic activity of OFQ/N given spinally than supraspinally (Rossi et al., 1996, 1997; Xu et al., 1996a; King et al., 1997b). In the current studies we confirmed the presence of a potent OFQ/N analgesia after intrathecal administration that was markedly enhanced in the D2 receptor knock-out mice.

The anatomical site of the physiological interactions between the D2 receptor and opioid systems remains unclear. Many regions contain both D2 and opioid receptors, such as lamina I within the spinal cord and a variety of supraspinal structures (Khachaturian and Watson, 1982; Curran and Watson, 1995; van Dijken et al., 1996; Khan et al., 1998), raising the possibility of direct D2 receptor-opioid interactions. However, there is no evidence that the D2 receptor system acts directly on circuits containing opioid neurons, leaving open the possibility that this system modulates analgesia through intermediary neuronal circuits or possibly even at higher levels of sensory integration. There are some indications that supraspinal µ and delta  opioid receptors are downregulated supraspinally in the knock-out mice, whereas kappa 1 opioid receptors and nociceptin/orphanin FQ (NOP1 or ORL1) receptors are upregulated both supraspinally and spinally (I. Kitchen and J. E. Pintar, unpublished observations). However, these changes are quite modest and their significance remains to be demonstrated.

In knock-out mice, behavioral changes may simply reflect the loss of the targeted protein, but the question of compensatory developmental changes also must be considered. Antisense approaches can avoid some of these problems. Although the degree of downregulation is often limited, the technique can be applied to adult animals, eliminating potential developmental effects. Antisense studies have been used effectively against D2 receptors in the past (Weiss et al., 1993, 1997; Zhang and Creese, 1993; Creese and Tepper, 1998). In our studies, antisense treatment gave results that were indistinguishable from those seen in the knock-out model. Downregulation of D2 receptors supraspinally potentiated µ and kappa  analgesia without affecting delta  systems. The similar findings in both the knock-out and antisense paradigms imply that actions are attributable to a loss of the D2 receptor itself and are not a result of compensatory developmental changes in the knock-out mice.

The sigma 1 receptor system also modulates opioid activity. Indeed, the differences in opioid sensitivity among some strains result from varying tonic levels of sigma 1 receptor activity (Chien and Pasternak, 1993, 1994). Haloperidol has been used extensively to explore the effects of sigma  systems. However, haloperidol has high affinity for both D2 and sigma  receptor systems, making conclusions difficult. The knock-out mice provided a model to explore the relationship between the two systems. The persistent ability of the sigma 1 agonist (+)-pentazocine to lower morphine analgesia in the D2 knock-out mice demonstrated the continued presence of the sigma 1 receptor system in these animals. In addition, the reversal of this action by haloperidol confirmed its activity as a sigma 1 antagonist. Thus, the anti-opioid sigma 1 system is independent of the dopamine D2 receptor system.

In conclusion, the modulation of opioid analgesia by other neurotransmitter systems is complex. Many systems facilitate opioid actions, whereas others are inhibitory. The current studies in mice with a disruption of the dopamine D2 receptor reveal an important modulatory role for this dopamine that may be used clinically in the management of pain.


    FOOTNOTES

Received March 1, 2001; revised July 17, 2001; accepted July 18, 2001.

This work was supported by National Institute on Drug Abuse Grants DA08622 (J.E.P.); DA07241, DA02615, and DA00220 (G.W.P.); and T32DA07274 (M.A.K.) and by National Cancer Institute Core Grant CA08748 to Memorial Sloan-Kettering Cancer Center.

Correspondence should be addressed to Dr. Gavril Pasternak, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: pasterng{at}mskcc.org.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

  • Azaryan AV, Clock BJ, Cox BM (1996) µ opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem Res 21:1411-1415[Medline].
  • Bodnar RJ, Nicotera N (1982) Neuroleptic and analgesic interactions upon pain and activity measures. Pharmacol Biochem Behav 16:411-416[Medline].
  • Brent PJ, Bunn SJ (1994) In vivo treatment with µ and delta , but not kappa -selective opioid agonists reduces [3H]spiperone binding to the guinea pig striatum: autoradiographic evidence. Brain Res 654:191-199[Medline].
  • Calcutt CR, Doggett NS, Spencer PSJ (1971) Modification of the anti-nociceptive activity of morphine by centrally administered ouabain and dopamine. Psychopharmacologia 21:111-117.
  • Cesselin F (1995) Opioid and anti-opioid peptides. Fundam Clin Pharmacol 9:409-433[Medline].
  • Chien C-C, Pasternak GW (1993) Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid sigma 1 system. Eur J Pharmacol 250:R7-R8[Medline].
  • Chien C-C, Pasternak GW (1994) Selective antagonism of opioid analgesia by a sigma  system. J Pharmacol Exp Ther 271:1583-1590[Abstract/Free Full Text].
  • Chien C-C, Pasternak GW (1995a) (-)-Pentazocine analgesia in mice: interactions with a sigma  receptor system. Eur J Pharmacol 294:303-308[Medline].
  • Chien C-C, Pasternak GW (1995b) sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 190:137-139[Medline].
  • Creese I, Tepper JM (1998) Antisense knockdown of brain dopamine receptors. Adv Pharmacol 42:517-520.
  • Curran EJ, Watson Jr SJ (1995) Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in situ hybridization study. J Comp Neurol 361:57-76[Web of Science][Medline].
  • Faris PL, Komisaruk BR, Watkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:310-312[Abstract/Free Full Text].
  • Grisel JE, Mogil JS, Belknap JK, Grandy DK (1996) Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. NeuroReport 7:2125-2129[Web of Science][Medline].
  • Guiramand J, Montmayeur JP, Ceraline J, Bhatia M, Borrelli E (1995) Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 270:7354-7358[Abstract/Free Full Text].
  • Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12:12-15[Medline].
  • Hong JS, Yang H-YT, Fratta W, Costa E (1978) Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs. J Pharmacol Exp Ther 205:141-147[Free Full Text].
  • Hylden JLK, Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316[Web of Science][Medline].
  • Jung MY, Skryabin BV, Arai M, Abbondanzo S, Fu D, Brosius J, Robakis NK, Polites HG, Pintar JE, Schmauss C (1999) Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience 91:911-924[Web of Science][Medline].
  • Kamei J, Saitoh A (1996) Involvement of dopamine D2 receptor-mediated functions in the modulation of morphine-induced antinociception in diabetic mouse. Neuropharmacology 35:273-278[Medline].
  • Khachaturian H, Watson SJ (1982) Some perspectives on monoamine-opioid peptide interaction in rat central nervous system. Brain Res Bull 9:441-462[Medline].
  • Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la CA (1998) Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J Comp Neurol 402:353-371[Web of Science][Medline].
  • King M, Chang A, Pasternak GW (1998) Functional blockade of opioid analgesia by orphanin FQ/nociceptin. Biochem Pharmacol 55:1537-1540[Medline].
  • King MA, Pan Y-X, Mei J, Chang A, Xu J, Pasternak GW (1997a) Enhanced kappa  opioid analgesia by antisense targeting the sigma 1 receptor. Eur J Pharmacol 331:R5-R7[Medline].
  • King MA, Rossi GC, Chang AH, Williams L, Pasternak GW (1997b) Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. Neurosci Lett 223:113-116[Web of Science][Medline].
  • Kunihara M, Ohyama M, Nakano M (1993) Effects of spiradoline mesylate, a selective kappa -opioid receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia. Jpn J Pharmacol 62:223-230[Medline].
  • Luke MC, Hahn EF, Price M, Pasternak GW (1988) Irreversible opiate agonists and antagonists. V. Hydrazone and acylhydrazones: derivatives of naltrexone. Life Sci 43:1249-1256[Medline].
  • Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E (1997) Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388:586-589[Medline].
  • McGilliard KL, Takemori AE (1979) The effect of dopaminergic modifiers on morphine-induced analgesia and respiratory depression. Eur J Pharmacol 54:61-68[Medline].
  • Mei J, Pasternak GW (2001) Molecular cloning and pharmacological characterization of the rat sigma 1 receptor. Biochem Pharmacol 62:349-355[Web of Science][Medline].
  • Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazargull H, Vassart G, Parmentier M, Costentin J (1995) Isolation and structure of the endogenous agonist of the opioid receptor-like ORL1 receptor. Nature 377:532-535[Medline].
  • Michael-Titus A, Bousselmame R, Costentin J (1990) Stimulation of dopamine D2 receptors induces an analgesia involving an opioidergic but nonenkephalinergic link. Eur J Pharmacol 187:201-207[Medline].
  • Mogil JS, Grisel JE, Reinscheid KK, Civelli O, Belknap JK, Grandy DK (1996) Orphanin FQ is a functional anti-opioid peptide. Neuroscience 75:333-337[Web of Science][Medline].
  • Montmayeur JP, Bausero P, Amlaiky N, Maroteaux L, Hen R, Borrelli E (1991) Differential expression of the mouse D2 dopamine receptor isoforms. FEBS Lett 278:239-243[Web of Science][Medline].
  • Morgan MJ, Franklin KB (1991) Dopamine receptor subtypes and formalin test analgesia. Pharmacol Biochem Behav 40:317-322[Web of Science][Medline].
  • Nichols ML, Bian D, Ossipov MH, Lai J, Porreca F (1995) Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. J Pharmacol Exp Ther 275:1339-1345[Abstract/Free Full Text].
  • Pan YX, Mei JF, Xu J, Wan BL, Zuckerman A, Pasternak GW (1998) Cloning and characterization of a sigma 1 receptor. J Neurochem 70:2279-2285[Web of Science][Medline].
  • Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792-794[Abstract/Free Full Text].
  • Rodgers RJ (1977) Attenuation of morphine analgesia in rats by intra-amygdaloid injection of dopamine. Brain Res 130:156-162[Medline].
  • Rooney KF, Sewell RD (1989) Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociception. Eur J Pharmacol 168:329-336[Medline].
  • Rossi G, Leventhal L, Bolan EA, Pasternak GW (1997) Pharmacological characterization of orphanin FQ/nociceptin and its fragments. J Pharmacol Exp Ther 282:858-865[Abstract/Free Full Text].
  • Rossi GC, Leventhal L, Pasternak GW (1996) Naloxone-sensitive orphanin FQ-induced analgesia in mice. Eur J Pharmacol 311:R7-R8[Web of Science][Medline].
  • Roumy M, Zajac JM (1998) Neuropeptide FF, pain, and analgesia. Eur J Pharmacol 345:1-11[Web of Science][Medline].
  • Spiegel K, Kourides IA, Pasternak GW (1982) Different receptors mediate morphine-induced prolactin and growth hormone release. Life Sci 31:2177-2180[Medline].
  • Standifer KM, Chien C-C, Wahlestedt C, Brown GP, Pasternak GW (1994) Selective loss of delta  opioid analgesia and binding by antisense oligodeoxynucleotides to a delta  opioid receptor. Neuron 12:805-810[Web of Science][Medline].
  • Suaudeau C, Costentin J (1995) Analgesic effect of the direct D2 dopamine receptor agonist RU 24926 and cross tolerance with morphine. Fundam Clin Pharmacol 9:147-152[Medline].
  • Tallarida RJ, Murray RB (1987) In: Manual of pharmacological calculations with computer programs. New York: Springer.
  • Tian JH, Xu W, Fang Y, Mogil JS, Grisel JE, Grandy DK, Han JS (1997) Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 120:676-680[Web of Science][Medline].
  • Tulunay FC, Sparber SB, Takemori AE (1975) The effect of dopaminergic stimulation and blockade on the nociceptive and antinociceptive responses of mice. Eur J Pharmacol 33:65-70[Web of Science][Medline].
  • van Dijken H, Dijk J, Voom P, Holstege JC (1996) Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 8:621-628[Web of Science][Medline].
  • Weiss B, Zhou L-W, Zhang S-P, Qin Z-H (1993) Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience 55:607-612[Web of Science][Medline].
  • Weiss B, Zhang S-P, Zhou L-W (1997) Antisense strategies in dopamine receptor pharmacology. Life Sci 60:433-455[Medline].
  • Wood PL (1983) Opioid regulation of CNS dopaminergic pathways: a review of methodology, receptor types, regional variations, and species differences. Peptides 4:595-601[Medline].
  • Wood PL, Pasternak GW (1983) Specific µ2 opioid isoreceptor regulation of nigrostriatal neurons: in vivo evidence with naloxonazine. Neurosci Lett 37:291-293[Web of Science][Medline].
  • Wood PL, Stotland M, Richard JW, Rackham A (1980) Actions of µ, kappa , sigma , delta , and agonist/antagonist opiates on striatal dopaminergic function. J Pharmacol Exp Ther 215:697-703[Free Full Text].
  • Xu XJ, Hao JX, Wiesenfeld-Hallin Z (1996a) Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. NeuroReport 7:2092-2094[Web of Science][Medline].
  • Xu XJ, Hoffmann O, Wiesenfeld-Hallin Z (1996b) L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies. Neuropeptides 30:203-206[Medline].
  • Zhang M, Creese I (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci Lett 161:223-226[Web of Science][Medline].

Copyright © 2001 Society for Neuroscience  0270-6474/01/21197788-05$05.00/0


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
J. Mei and G. W. Pasternak
Modulation of Brainstem Opiate Analgesia in the Rat by {sigma}1 Receptors: A Microinjection Study
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1278 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. J. Scott, M. M. Heitzeg, R. A. Koeppe, C. S. Stohler, and J.-K. Zubieta
Variations in the human pain stress experience mediated by ventral and dorsal Basal Ganglia dopamine activity.
J. Neurosci., October 18, 2006; 26(42): 10789 - 10795.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K.-S. Kim, K.-W. Lee, K.-W. Lee, J.-Y. Im, J. Y. Yoo, S.-W. Kim, J.-K. Lee, E. J. Nestler, and P.-L. Han
Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action.
PNAS, March 7, 2006; 103(10): 3908 - 3913.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
J. Ellrich
Electric Low-Frequency Stimulation of the Tongue Induces Long-Term Depression of the Jaw-Opening Reflex in Anesthetized Mice
J Neurophysiol, December 1, 2004; 92(6): 3332 - 3337.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. H. Tran, R. Tamura, T. Uwano, T. Kobayashi, M. Katsuki, G. Matsumoto, and T. Ono
Altered accumbens neural response to prediction of reward associated with place in dopamine D2 receptor knockout mice
PNAS, June 25, 2002; 99(13): 8986 - 8991.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M.-R. Zarrindast, Z. Dinkoub, H. Homayoun, A. Bakhtiarian, and S. Khavandgar
Dopamine receptor mechanism(s) and morphine tolerance in mice
J Psychopharmacol, May 1, 2002; 16(3): 261 - 266.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Mei and G. W. Pasternak
sigma 1 Receptor Modulation of Opioid Analgesia in the Mouse
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1070 - 1074.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (34)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, M. A.
Right arrow Articles by Pasternak, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, M. A.
Right arrow Articles by Pasternak, G. W.

-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-